I wanted to clarify some points about ImmunoQuery and the decisions I have made about its future.
First, I did try to give ImmunoQuery to CAP several years ago, giving a presentation to the Internet Editorial Board. They declined to take it (the pathologists of the board thought it was a good idea but the CAP staff people did not want to deal with it.)
Second, this is the first time ImmunoQuery is being commercialized. I did put a survey on the site several years ago to see the response to commercialization (actually was positive for the most part except for "third world" pathologists), but an attempt to commercialize was never done.
I was approached by Dr. Elizabeth Hammond from LDS Hospital about a year ago about incorporating ImmunoQuery into a pathology publishing product for the company, Amirsys, based in Salt Lake City, Utah. This physician-owned company has been successful in publishing
database images and radiographic information for Radiologists for several years, leading to several successful radiology publications and an online decision support system for radiology. Dr. Hammond has put together a team of lead pathologists such as Drs. Amin, Burger,
Colvin, DeEllis, Fisher, Foucar, Lester, and Wick, among others to do the same for pathology. ImmunoQuery will become the first release of the company as StatdxPathIQ which will be expanded by images, examples of pitfalls, and a new programming platform which will perform much better than the current database system. The other
authors will create a much larger system including pathology data and images from all of the organ systems. It was an offer I couldn't refuse. and I have become part of the company as Associate Editor. Yes, there is financial incentive, but my motive is much more than just that. I now have a programming team to undertake all of the administrative duties. I can now add images to the database which was something I always wanted to do but did not have the ability or time. Plus I can get the input of the top pathologists to ensure integrity and completeness of the data. And further plus, this ensures the continuation of ImmunoQuery beyond that of a one-man operation performed by a full-time community pathologist with little
free time.
I hope this clarifies somewhat what is happening with ImmunoQuery. I have always appreciated your support of the product in the past.